New Delhi, March 9:
Dr Reddy’s Laboratories today said it has received 13 observations from the US health regulator for its formulation manufacturing facility at Duwada, Visakhapatnam.
“The audit of company’s formulation manufacturing facility at Duwada, Visakhapatnam, by the USFDA had been completed on March 8, 2017. The company has been issued Form 483 with 13 observations, which the company is addressing,” Dr Reddy’s Laboratories said in a BSE filing.
The company, however, did not specify the observations.
Shares of Dr Reddy’s Laboratories were trading 4.21 per cent lower at Rs 2,731.35 on the BSE.
(This article was published on March 9, 2017)
Get more of your favourite news delivered to your inbox
Please enter your email. Thank You.
Newsletter has been successfully subscribed.